Zurich Cantonal Bank’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Zurich Cantonal Bank’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,787	Closed	-$134K	–	2669
2020 Q1	$134K	Buy	2,787 +1,206	+76%	+$56.1K	﹤0.01%	1432
2019 Q4	$74K	Sell	1,581 -950	-38%	-$42K	﹤0.01%	1917
2019 Q3	$60K	Sell	2,531 -483	-16%	-$14.3K	﹤0.01%	1912
2019 Q2	$91K	Hold	3,014	–	–	﹤0.01%	1682
2019 Q1	$68K	Buy	3,014 +1,868	+163%	+$40.2K	﹤0.01%	1819
2018 Q4	$21K	Buy	+1,146	New	+$18K	﹤0.01%	2441

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Zurich Cantonal Bank's RARX Position: Q2 2020 in Review

Zurich Cantonal Bank sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 2,787 shares — an estimated $134K sold.

Zurich Cantonal Bank first reported a position in RARX in Q4 2018 and held it in 6 quarters. The position peaked at $134K in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Zurich Cantonal Bank reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Zurich Cantonal Bank sold 2,787 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $134K.
Zurich Cantonal Bank first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Zurich Cantonal Bank's Ra Pharmaceuticals, Inc. Common Stock position peaked at $134K in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Zurich Cantonal Bank's 13F filing for Q2 2020, filed 28 Jul 2020.